Senores Pharmaceuticals IPO subscribed overall 97.86 times on the last day, while A retail quota was subscribed 93.16 times, QIB was subscribed 97.84 times, and NII quota subscribed by 100.35 times respectively.
Details About Senores Pharmaceuticals IPO
Senores Pharmaceuticals got approval from SEBI for an IPO of ₹582.11 crores to raise funds and maintain financial stability. The face value of each share was Rs 10 each. Moreover, the company has set up a price band between ₹372 to ₹391 per share. In this IPO total of 38 shares were available in 1 lot size for the minimum Retail category and for the maximum retail category 494 shares in 13 lot sizes. S-HNI (Min) has a total of 532 shares in 14 lot sizes, while B-HNI Minimum has a total of 2,584 shares available in 68 lot sizes.
To invest in this IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum investment of ₹14,858 and maximum investment of ₹1,93,154.
- Small HNI (S-HNI): Minimum investment of ₹2,08,012.
- Big HNI (S-HNI): Minimum investment of ₹10,10,344.
Subscription duration of Senores Pharmaceuticals IPO
The Senores Pharmaceuticals IPO subscription opening date was 20 December and the close date was 24 December. The Senores Pharmaceuticals IPO allotment was finalized on December 26 and the IPO listing is on December 30.
Funds Deployment of This Company
The company plans to use the money raised from the new shares for the following purposes:
- Funding the capital expenditure requirements by investment in of one of our Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility;
- Repayment/pre-payment, in full or in part, of certain borrowings availed by our Company and our Subsidiaries, namely, Havix, Ratnatris Pharmaceutical Private Limited (“Ratnatris”), and Senores Pharmaceuticals Inc. (“SPI”);
- Funding the working capital requirements of our Company and our Subsidiaries, namely, SPI and Ratnatris; and
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
About Senores Pharmaceuticals IPO
Senores Pharmaceutical is one of the leading firms for generic medicine, certified by global food and drug authorities. Moreover, nowadays they are committed to good quality and manufacturing products to create more demand in the global healthcare industry. They also have the aim of innovation, production, and manufacturing verticals and also have the vision to make more affordable and accessible healthcare, especially for varied types of products. Moreover, they are providing a dynamic strategy, offering them access to products that are good to go. Noticeably, they have the strength of identifying, producing, specialty, underpenetrated, and complex pharmaceutical products, and received the reliability of customers to choose them over and over. Further, the US and Canadian market is the current focus along with 43 countries that also feel their presence as well. The company also manufactures critical care injectables and active pharmaceutical ingredients (APIs).
Senores Pharmaceuticals IPO Financial Background
The company reported revenue of ₹217.34 crores in 2024 against ₹39.02 crores in 2023. The company reported a loss of ₹32.71 crores in 2024 against a Profit of ₹8.43 crores in 2023.
